摘要
近年来,多项临床随机对照研究表明与保守治疗相比经导管肝动脉化疗栓塞术(TACE)治疗中晚期肝癌(HCC)取得了良好的临床疗效。随着栓塞材料的发展,新型微粒栓塞剂因具有生物相容性、药物缓释作用等优点而成为临床研究的热点,有望进一步提升TACE治疗肝癌的临床疗效。目前国内外已有多种微粒型栓塞剂应用于临床,现将其生物特性及临床疗效做如下综述。
In recent years, a great deal of randomized controlled trials have indicated that transcatheter hepatic arterial chemoembolization （TACE） is more effective than conservative medication in treating mid-stage and advanced hepatocellular carcinoma （HCC）. With the development of the embolic materials, the new microparticle embolic agents have become the hot topics in clinical research as these new agents have many advantages such as fine biocompatibility, slow-releasing of drug, etc. It is quite hopeful that the use of the new microparticle embolic agents may further improve the clinical curative effect of TACE for HCC. Up till the present moment, there are many kinds of microparticle embolic agents used in clinical practice at home and abroad. This paper aims to make a comprehensive review about the microparticte embolic agents, focusing on their biological properties and clinical effectiveness.
出处
《介入放射学杂志》
CSCD
北大核心
2012年第11期969-972,共4页
Journal of Interventional Radiology
关键词
微粒型栓塞剂
肝癌
肝动脉化疗栓塞术
microparticle embolic agent
hepatocellular carcinoma
transcatheter hepatic arterial chemoembolization
